Ovid Therapeutics Inc. 8-K Filing
Ticker: OVID · Form: 8-K · Filed: 2025-12-18T00:00:00.000Z
Sentiment: neutral
Filing Stats: 434 words · 2 min read · ~1 pages · Grade level 10.3 · Accepted 2025-12-18 08:39:41
Key Financial Figures
- $0.001 — hich registered Common Stock par value $0.001 per share OVID The Nasdaq Stock Mar
Filing Documents
- d84904d8k.htm (8-K) — 24KB
- d84904dex991.htm (EX-99.1) — 20KB
- g84904g1218105026102.jpg (GRAPHIC) — 7KB
- 0001193125-25-323798.txt ( ) — 170KB
- ovid-20251218.xsd (EX-101.SCH) — 3KB
- ovid-20251218_lab.xml (EX-101.LAB) — 18KB
- ovid-20251218_pre.xml (EX-101.PRE) — 11KB
- d84904d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated December 18, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized Date: December 18, 2025 OVID THERAPEUTICS INC. By: /s/ Jeffrey Rona Jeffrey Rona Chief Business and Financial Officer